Artiva Biotherapeutics, Inc.
Number not stated
SEC filingAnnounced
Artiva Biotherapeutics, Inc. discloses a restructuring plan in an SEC filing
- Industry
- Biotech
- Filed with the SEC
- October 27, 2026
- Share of workforce
- 94%
- Whose workers
- Scope not stated
- In the report for
- October 28, 2026
What happened
Artiva Biotherapeutics, Inc. disclosed a restructuring plan in an SEC filing without stating how many jobs it affects. The filing puts the reduction at about 94% of its workforce.
Sources
SEC EDGAR · SEC filing · Oct 27, 2026
On October 22, 2026, the board of directors of the Company approved the discontinuation of the Company’s development of AlloNK ® (AB-101), its non-genetically modified, allogeneic natural killer (NK) cell therapy candidate, as the Company conducts a process to explore strategic alternatives to maximize stockholder value, which includes a plan to implement a reduction of the Company’s workforce by approximately 94% of the Company’s current employee base (the “Wind Down”).
Read the source